Endologix Inc. (NASDAQ:ELGX) – Stock analysts at Oppenheimer Holdings reduced their FY2017 EPS estimates for shares of Endologix in a research note issued on Monday. Oppenheimer Holdings analyst S. Lichtman now expects that the firm will earn ($0.58) per share for the year, down from their previous forecast of ($0.55). Oppenheimer Holdings has a “Outperform” rating and a $15.00 price target on the stock. Oppenheimer Holdings also issued estimates for Endologix’s FY2018 earnings at ($0.22) EPS.
Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. The firm had revenue of $51 million for the quarter, compared to analyst estimates of $46.30 million. Endologix had a negative net margin of 82.39% and a negative return on equity of 41.88%. The business’s revenue for the quarter was up 29.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.18) EPS.
ELGX has been the topic of several other reports. Guggenheim assumed coverage on shares of Endologix in a research report on Wednesday, June 8th. They set a “buy” rating and a $16.00 target price on the stock. BTIG Research reiterated a “buy” rating and issued a $16.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. Royal Bank Of Canada lowered shares of Endologix from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $17.00 to $12.00 in a research report on Wednesday, August 3rd. Leerink Swann assumed coverage on shares of Endologix in a research report on Tuesday, September 6th. They issued a “market perform” rating and a $13.00 price target on the stock. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $15.00 price target on shares of Endologix in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company’s stock. Endologix currently has a consensus rating of “Buy” and an average target price of $13.79.
Endologix (NASDAQ:ELGX) traded up 3.79% during mid-day trading on Wednesday, reaching $12.86. 412,759 shares of the company traded hands. The stock has a 50-day moving average of $12.29 and a 200 day moving average of $11.80. The stock’s market capitalization is $1.06 billion. Endologix has a 52-week low of $6.51 and a 52-week high of $14.50.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. raised its stake in Endologix by 4.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,827,084 shares of the company’s stock worth $15,274,000 after buying an additional 79,354 shares during the last quarter. NN Investment Partners Holdings N.V. purchased a new stake in Endologix during the first quarter worth $662,000. Palisade Capital Management LLC NJ raised its stake in Endologix by 3.9% in the first quarter. Palisade Capital Management LLC NJ now owns 2,138,230 shares of the company’s stock worth $17,876,000 after buying an additional 80,944 shares during the last quarter. AXA raised its position in shares of Endologix by 52.4% in the first quarter. AXA now owns 585,437 shares of the company’s stock valued at $4,894,000 after buying an additional 201,395 shares in the last quarter. Finally, Altrinsic Global Advisors LLC raised its position in shares of Endologix by 9.4% in the first quarter. Altrinsic Global Advisors LLC now owns 580,000 shares of the company’s stock valued at $4,849,000 after buying an additional 50,000 shares in the last quarter.
In related news, VP Jose A. Lima sold 4,710 shares of the firm’s stock in a transaction on Friday, August 19th. The shares were sold at an average price of $11.68, for a total transaction of $55,012.80. Following the completion of the sale, the vice president now directly owns 42,594 shares of the company’s stock, valued at approximately $497,497.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Michael V. Chobotov sold 14,000 shares of the firm’s stock in a transaction on Friday, August 5th. The shares were sold at an average price of $12.40, for a total transaction of $173,600.00. Following the sale, the insider now directly owns 189,269 shares of the company’s stock, valued at $2,346,935.60. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.